Supreme Court Weighs Fifth Circuit Ruling Restricting Mail Delivery of Abortion Medication Mifepristone
By
Tessa Stuart
22d ago· 4 min readenNews
78/100
Toasty
Bagelometer↗
Crispy enough to crunch, soft enough to enjoy. A good bake.
Score78TypenewsSentimentnegative
Summary
The Supreme Court is considering whether to uphold a Fifth Circuit ruling that would prohibit abortion providers from mailing mifepristone, the most commonly used abortion medication in the U.S. The case, Louisiana v. FDA, has caused legal whiplash as access to the drug was revoked and restored within a week and a half. The ruling specifically targets the mailing of mifepristone, which is the first drug in the standard two-step medication abortion protocol. This case represents another significant legal challenge to abortion access following the Dobbs decision.
Key quotes
· 3 pulledAmerican women and doctors are, once again, experiencing whiplash as the court system has revoked and restored access to the most widely used abortion medication in the country — and is poised to strip it away once more — all in the span of a week and a half.
Last Friday, the Fifth Circuit Court of Appeals issued a ruling in Louisiana v. FDA, prohibiting abortion providers from mailing mifepristone, the first drug taken as part of the typical two-step medication abortion protocol, to patients anywhere in the county.
The following Monday, the Supreme Court temporarily reinstated access
The Supreme Court is considering whether to uphold a lower court ruling prohibiting abortion providers from mailing mifepristone.
